文献速递产科母胎医学

双胎产前暴露于17-α羟孕酮己酸酯与儿童结局:随机试验14年随访

Prenatal 17-Alpha-Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14-Year Follow-Up of a Randomised Trial.
PubMed 文献 · BJOG · 2026-03-23

该研究为AMPHIA随机对照试验的14年随访,评估多胎妊娠孕妇每周注射17-OHPC或安慰剂后子代的长期结局。结果显示,17-OHPC组与安慰剂组在儿童死亡率、教育程度、认知、行为、性别认同及总体健康方面均无显著差异,异常发育复合结局亦无差异。

要点

  • 多胎妊娠产前17-OHPC暴露与儿童14岁时死亡率无显著差异(OR 0.75,95%CI 0.36-1.53)。
  • 17-OHPC组与安慰剂组教育程度、认知、行为、性别认同及总体健康均无显著差异。
  • 异常发育复合结局在17-OHPC组为23.3%,安慰剂组为20.1%(OR 1.31,95%CI 0.66-2.56),无统计学差异。

核心结论

  • 多胎妊娠孕妇孕期使用17-OHPC对子代死亡率、教育程度、认知和行为等结局不太可能产生正面或负面影响。

研究设计与样本

  • AMPHIA随机对照试验的随访研究,比较每周注射17-OHPC与安慰剂的多胎妊娠子代结局。
  • 子代在11-14岁时通过记录链接及父母和教师问卷评估。
  • 采用 twins 聚类稳健标准误和逆概率加权(IPW)调整混杂因素。

主要发现

  • 至14岁,1356名儿童中60名死亡(17-OHPC组24名,安慰剂组36名;OR 0.75,95%CI 0.36-1.53)。
  • 存活儿童中1027/1296(79%)完成记录链接(17-OHPC组517名,安慰剂组510名),教育程度无显著差异。
  • 303/1296(23%)存活儿童通过问卷收集详细发育结局(17-OHPC组159名,安慰剂组144名),认知、行为、性别认同和总体健康均无差异。
  • 异常发育复合结局:17-OHPC组23.3%,安慰剂组20.1%(OR 1.31,95%CI 0.66-2.56)。

临床怎么用

  • 对于多胎妊娠,产前17-OHPC暴露未显示对子代14岁时死亡率、教育程度、认知和行为等结局有显著影响。

局限性

  • 问卷详细发育结局的收集率较低(23%),可能影响结果的代表性。
  • 记录链接完成率为79%,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term child outcomes after intra-uterine exposure to 17-alpha-hydroxyprogesterone caproate (17-OHPC) versus placebo. DESIGN: Follow-up of the AMPHIA randomised controlled trial assessing neonatal outcomes after weekly 17-OHPC injections compared to placebo in multiple pregnancies. SETTING: Multicentre. POPULATION OR SAMPLE: Children born in the AMPHIA study. METHODS: Children were assessed at 11-14 years of age by record linkage and through self-reported, parental and teacher questionnaires. Mean differences or odds ratios (OR) with 95% confidence intervals (95% CI) were calculated with cluster robust standard errors for twins and adjustment for confounders using inverse probability weighting (IPW). MAIN OUTCOME MEASURES: Child mortality, educational attainment, cognition, behaviour, gender identity, general health, and a composite of abnormal development. RESULTS: Up to 14 years, 60/1356 children had died (n = 24 17-OHPC and n = 36 placebo (OR 0.75 95% CI 0.36-1.53)). Record linkage was completed for 1027/1296 (79%) surviving children (n = 517 17-OHPC and n = 510 placebo). No significant difference was found regarding educational attainment. Detailed developmental outcomes through questionnaires were collected for 303/1296 (23%) surviving children (n = 159 17-OHPC and n = 144 placebo). No differences in cognition, behaviour, gender identity, and general health up to 14 years of age were found between both groups. The composite of abnormal development did not differ between 17-OHPC (23.3%) and placebo (20.1%) groups (OR 1.31 95% CI 0.66-2.56). CONCLUSION: In offspring of women with a multiple pregnancy, the use of 17-OHPC in pregnancy is unlikely to provide positive or negative effects on child outcome related to mortality, educational attainment, cognition and behaviour.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. van Limburg Stirum EVJ, de Boer MA, Ravelli ACJ, et al. Prenatal 17-Alpha-Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14-Year Follow-Up of a Randomised Trial. BJOG. 2026. PMID: 41872711. doi:10.1111/1471-0528.70223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。